https://www.selleckchem.com/pr....oducts/Neratinib(HKI
while the inhibition of HOXA10 or HDAC1 represents a promising anti-tumor therapy target for LAD. One objective of the Belgian Rare Diseases plan is to improve patients' management using phenotypic tests and, more specifically, the access to those tests by identifying the biochemical analyses used for rare diseases, developing new financing conditions and establishing reference laboratories. A feasibility study was performed from May 2015 until August 2016 in order to select the financeable biochemical analyses, and, among th
Like
Comment
Share
